To investigate the overall association of 89Zr-DFO-6E11 tumour uptake and immunotherapeutic response to anti-PD-L1 therapy, the percent tumour growth increase at multiple days post-treatment initiation was calculated and plotted against the mean and maximum tumour-to-muscle ratios of 89Zr-DFO-6E11. This evidence concerns the gene CD274 and neoplasm.